Sibylla Biotech Raises €23 Million Series A To Advance Protein Degradation By Folding Interference Pipeline And Expand Technology Platform
Amount Raised
€23 Million
Round Type
Series A
BressoManufacturingBiotechnologyFood And BeverageDescription
Sibylla Biotech today announced the successful close of its €23 million Series A financing round to fund the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, which provides access to a new class of pharmacological targets that transiently appear during the process of protein folding, and to advance its proprietary pipeline programs through preclinical evaluation. The financing from an international syndicate of specialized life science investors was led by V-Bio Ventures with participation from Seroba Life Sciences, 3B Future Health Fund, Claris Ventures, CDP Venture Capital with Evolution Fund, VI Partners, Indaco Venture Partners, as well as the company’s seed investor, Vertis SGR. Concurrent with the close of the fundraising, Ward Capoen from V-Bio, Bruno Montanari from Seroba, Ciro Spedaliere from Claris Ventures, and Marianne Bjordal from 3B Future Health Fund will join Sibylla’s Board of Directors.
Quick answer
Sibylla Biotech raised €23 Million in a Series A round, dated October 4, 2022. Sibylla Biotech is based in Bresso, Lombardy, Italy.
- How much did Sibylla Biotech raise?
- Sibylla Biotech raised €23 Million in a Series A round on October 4, 2022.
- What does Sibylla Biotech do?
- Sibylla is disrupting the protein degradation landscape by applying a novel mechanism of action that interferes with protein folding and thereby suppresses the expression of a disease-relevant protein.
- Where is Sibylla Biotech based and how big is it?
- Sibylla Biotech is based in Bresso, Lombardy, Italy. Fundz records about 41 employees.
- Who are the decision-makers at Sibylla Biotech?
- Fundz holds 2 contacts at Sibylla Biotech. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Food And Beverage and Manufacturing around the same time
Companies in the same sectors as Sibylla Biotech that raised within 45 days of this round, from Fundz verified event records.
- MedX Health raised an undisclosed amount (Convertible Note) on November 18, 2022.
- Alvotech raised an undisclosed amount (Funding Round) on November 16, 2022.
- The Shape Sensing Company raised an undisclosed amount (Funding Round) on November 10, 2022.
- Biocoat raised an undisclosed amount on November 2, 2022.
- Cerus raised an undisclosed amount (Grant) on November 2, 2022.
- Vitro3D raised $1.3M (Seed) on November 2, 2022.
Who to call at Sibylla Biotech, and when
A new round usually means Sibylla Biotech is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Sibylla Biotech raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Sibylla Biotech, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Sibylla Biotech. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Sibylla Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSibylla Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.